This observational study seeks to define a biomarker that will distinguish people with Alzheimer's disease from healthy, elderly control subjects. The study will enroll 50 subjects with Alzheimer's, 50 normal controls and approximately 20 subjects with non-Alzheimer's dementia. There will be two visits (up to 30 days apart), and a telephone follow-up visit.
|Min Age||Max Age||Gender||Healthy Volunteers|
Participants with Alzheimer's
The biomarker is measured by a ratio of the levels of two proteins, tau and Aβ42, found in cerebrospinal fluid. The investigators hypothesize that a cutoff value can be found that has at least 80 percent sensitivity and 60 percent specificity. This study will enroll 50 participants with Alzheimer's disease, 50 normal controls, and approximately 20 subjects with non-Alzheimer's dementia. There will be two visits (up to 30 days apart) and a telephone follow-up visit. This protocol does not include treatment for Alzheimer's or any other dementia. A lumbar puncture and blood tests will be done.
|Map Marker||City||State||Zip Code||Status||Primary Contact|
Geolocation is 36.025609, -78.9853813
James Burke, MD, PhD
Duke University Medical Center